{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:46:27Z","timestamp":1791229587334,"version":"4.1.0"},"reference-count":62,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Mycosis fungoides (MF) is the commonest subtype of cutaneous lymphoma, characterized by the infiltration of malignant T-cell clones into the skin. It accounts for approximately 60% of all cutaneous T-cell lymphoma diagnoses. MF has three distinct clinical stages \u2013 patch, plaque and tumour \u2013 presenting most commonly on the buttocks, trunk and breast. The presentation often mimics common inflammatory dermatoses such as eczema and psoriasis. Despite numerous theories, the aetiology of MF remains mostly unknown. Since its first description in 1806, diagnosis has remained a challenge and requires careful clinicopathological correlation. Patients may require multiple skin biopsies, especially at the patch stage, to identify the characteristic epidermotropic infiltrates of small-to-medium-sized lymphocytes. First-line management involves skin-directed therapies such as topical corticosteroids and phototherapy. If these are unsuccessful, systemic medications such as interferon-\u03b1, oral bexarotene, methotrexate and novel antibody therapies are trialled. MF can also respond to localized radiotherapy, total skin electron beam therapy and haematopoietic stem cell transplantation. Despite being primarily a cutaneous lymphoma, MF can progress to involve other organs. This review provides a comprehensive overview of the epidemiology, clinical features, diagnosis and management of MF.<\/jats:p>","DOI":"10.1093\/ced\/llaf341","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T11:25:54Z","timestamp":1753701954000},"page":"2365-2375","source":"Crossref","is-referenced-by-count":13,"title":["Mycosis fungoides: a review"],"prefix":"10.1093","volume":"50","author":[{"given":"Charlotte","family":"Sheern","sequence":"first","affiliation":[{"name":"Norwich Medical School, University of East Anglia , Norwich ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick J","family":"Levell","sequence":"additional","affiliation":[{"name":"Norwich Medical School, University of East Anglia , Norwich ,","place":["UK"]},{"name":"Department of Dermatology, Norfolk and Norwich University Hospital , Norwich ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J","family":"Craig","sequence":"additional","affiliation":[{"name":"Cellular Pathology, North Bristol NHS Trust , Bristol ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polly","family":"Jeffrey","sequence":"additional","affiliation":[{"name":"National Disease Registration Service, NHS Digital , Leeds ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4770-9335","authenticated-orcid":false,"given":"Khaylen","family":"Mistry","sequence":"additional","affiliation":[{"name":"Norwich Medical School, University of East Anglia , Norwich ,","place":["UK"]},{"name":"Department of Dermatology, Norfolk and Norwich University Hospital , Norwich ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew\u00a0J","family":"Scorer","sequence":"additional","affiliation":[{"name":"University Hospitals of Leicester , Leicester ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe C","family":"Venables","sequence":"additional","affiliation":[{"name":"Norwich Medical School, University of East Anglia , Norwich ,","place":["UK"]},{"name":"Department of Dermatology, Norfolk and Norwich University Hospital , Norwich ,","place":["UK"]},{"name":"National Disease Registration Service, NHS Digital , Leeds ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"key":"2025112512425141000_llaf341-B1","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood"},{"key":"2025112512425141000_llaf341-B2","volume-title":"Description des maladies de la peau observ\u00e9es a l\u2019h\u00f4pital Saint-Louis, et exposition des meilleures m\u00e9thodes suivies pour leur traitement","author":"Alibert","year":"1806"},{"key":"2025112512425141000_llaf341-B3","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/ajh.24233","article-title":"Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management","volume":"91","author":"Wilcox","year":"2015","journal-title":"Am J Haematol"},{"issue":"S1","key":"2025112512425141000_llaf341-B4","doi-asserted-by":"crossref","first-page":"i6","DOI":"10.1093\/bjd\/ljae090.010","article-title":"A national retrospective cohort study of the incidence and trends of 3061 cases of cutaneous T-cell lymphoma in England between 2013 and 2020","volume":"191","author":"Sheern","year":"2024","journal-title":"Br J Dermatol"},{"key":"2025112512425141000_llaf341-B5","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1111\/bjd.19644","article-title":"Epidemiological changes in cutaneous lymphomas: an analysis of 8593 patients from the French Cutaneous Lymphoma Registry","volume":"184","author":"Dobos","year":"2021","journal-title":"Br J Dermatol"},{"key":"2025112512425141000_llaf341-B6","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1001\/jamaoncol.2022.3236","article-title":"Incidence trends of primary cutaneous T-cell lymphoma in the US from 2000 to 2018: A SEER population data analysis","volume":"8","author":"Cai","year":"2022","journal-title":"JAMA Oncol"},{"key":"2025112512425141000_llaf341-B7","author":"Public Health England"},{"key":"2025112512425141000_llaf341-B8","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/bjd.20048","article-title":"Incidence of mycosis fungoides and S\u00e9zary syndrome in the Netherlands between 2000 and 2020","volume":"185","author":"Ottevanger","year":"2021","journal-title":"Br J Dermatol"},{"key":"2025112512425141000_llaf341-B9","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1111\/ijd.16098","article-title":"Mycosis fungoides in pediatric population: comprehensive review on epidemiology, clinical presentation, and management","volume":"61","author":"Kothari","year":"2022","journal-title":"Int J Dermatol"},{"issue":"S1","key":"2025112512425141000_llaf341-B10","doi-asserted-by":"crossref","first-page":"i46","DOI":"10.1093\/bjd\/ljae090.095","article-title":"A history of mycosis fungoides: from Alibert to mogamulizumab","volume":"191","author":"Johnson","year":"2024","journal-title":"Br J Dermatol"},{"key":"2025112512425141000_llaf341-B11","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1200\/JCO.2009.27.7665","article-title":"Survival outcomes and prognostic factors in mycosis fungoides\/S\u00e9zary syndrome: validation of the revised International Society for Cutaneous Lymphomas\/European Organisation for Research and Treatment of Cancer staging proposal","volume":"28","author":"Agar","year":"2010","journal-title":"J Clin Oncol"},{"key":"2025112512425141000_llaf341-B12","doi-asserted-by":"crossref","first-page":"1141108","DOI":"10.3389\/fonc.2023.1141108","article-title":"Mycosis fungoides and S\u00e9zary syndrome: clinical presentation, diagnosis, staging, and therapeutic management","volume":"13","author":"Miyashiro","year":"2023","journal-title":"Front Oncol"},{"key":"2025112512425141000_llaf341-B13","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/ijd.13967","article-title":"Immune privilege disruption in folliculotropic mycosis fungoides: investigation of major histocompatibility complex antigen expression","volume":"57","author":"Jayana","year":"2018","journal-title":"Int J Dermatol"},{"key":"2025112512425141000_llaf341-B14","doi-asserted-by":"crossref","first-page":"355","DOI":"10.5603\/AHP.2021.0068","article-title":"Folliculotropic mycosis fungoides","volume":"52","author":"Soko\u0142owska-Wojdy\u0142o","year":"2021","journal-title":"Acta Haematol Pol"},{"key":"2025112512425141000_llaf341-B15","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1067\/moe.2003.3","article-title":"Pagetoid reticulosis: a case report and review of the literature","volume":"95","author":"Sedghizadeh","year":"2003","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"2025112512425141000_llaf341-B16","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/bjd.21699","article-title":"Granulomatous slack skin: clinical characteristics, prognosis and response to therapy. A study from the Cutaneous Lymphoma French Study Group","volume":"187","author":"Barresti","year":"2022","journal-title":"Br J Dermatol"},{"key":"2025112512425141000_llaf341-B17","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/cyto.b.21888","article-title":"S\u00e9zary syndrome and mycosis fungoides: an overview, including the role of immunophenotyping","volume":"100","author":"Pulitzer","year":"2020","journal-title":"Cytometry B Clin Cytom"},{"key":"2025112512425141000_llaf341-B18","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.semcancer.2021.12.003","article-title":"Molecular pathogenesis of cutaneous T cell lymphoma: role of chemokines, cytokines, and dysregulated signaling pathways","volume":"86","author":"Patil","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"2025112512425141000_llaf341-B19","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.3390\/cells12121616","article-title":"Is cutaneous T-cell lymphoma caused by ultraviolet radiation? A comparison of UV mutational signatures in malignant melanoma and mycosis fungoides","volume":"12","author":"Gniadecki","year":"2023","journal-title":"Cells"},{"key":"2025112512425141000_llaf341-B20","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/bjd.17240","article-title":"British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018","volume":"180","author":"Gilson","year":"2019","journal-title":"Br J Dermatol"},{"key":"2025112512425141000_llaf341-B21","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.ijwd.2021.04.004","article-title":"A clinician\u2019s guide to cutaneous T-cell lymphoma presenting as recalcitrant eczematous dermatitis in adults","volume":"7","author":"Semaan","year":"2021","journal-title":"Int J Womens Dermatol"},{"key":"2025112512425141000_llaf341-B22","volume-title":"WHO Classification of Tumours","author":"WHO Classification of Tumours Editorial Board","year":"2023","edition":"5th edn"},{"key":"2025112512425141000_llaf341-B23","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s40257-022-00732-w","article-title":"Real-life barriers to diagnosis of early mycosis fungoides: an international expert panel discussion","volume":"24","author":"Hodak","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"2025112512425141000_llaf341-B24","author":"Emanuel"},{"key":"2025112512425141000_llaf341-B25","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.5858\/arpa.2014-0298-CC","article-title":"Selected inflammatory imitators of mycosis fungoides: histologic features and utility of ancillary studies","volume":"138","author":"Arps","year":"2014","journal-title":"Arch Pathol Lab Med"},{"key":"2025112512425141000_llaf341-B26","doi-asserted-by":"crossref","first-page":"264","DOI":"10.5732\/cjc.010.10344","article-title":"Diagnostic significance of TCR gene clonal rearrangement analysis in early mycosis fungoides","volume":"30","author":"Xu","year":"2011","journal-title":"Chin J Cancer"},{"key":"2025112512425141000_llaf341-B27","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.jaad.2007.06.004","article-title":"T-cell clonality analysis in biopsy specimens from two different skin sites shows high specificity in the diagnosis of patients with suggested mycosis fungoides","volume":"57","author":"Thurber","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"2025112512425141000_llaf341-B28","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","article-title":"Revisions to the staging and classification of mycosis fungoides and S\u00e9zary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood"},{"key":"2025112512425141000_llaf341-B29","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1001\/archdermatol.2008.46","article-title":"Granulomatous mycosis fungoides and granulomatous slack skin: a multicenter study of the Cutaneous Lymphoma Histopathology Task Force Group of the European Organization For Research and Treatment of Cancer (EORTC)","volume":"144","author":"Kempf","year":"2008","journal-title":"Arch Dermatol"},{"key":"2025112512425141000_llaf341-B30","doi-asserted-by":"crossref","first-page":"113343","DOI":"10.1016\/j.ejca.2023.113343","article-title":"EORTC consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome \u2013 update 2023","volume":"195","author":"Latzka","year":"2023","journal-title":"Eur J Cancer"},{"key":"2025112512425141000_llaf341-B31","doi-asserted-by":"crossref","first-page":"474","DOI":"10.5021\/ad.2011.23.4.474","article-title":"Narrowband ultraviolet B phototherapy of early stage mycosis fungoides in Korean patients","volume":"23","author":"Jang","year":"2011","journal-title":"Ann Dermatol"},{"key":"2025112512425141000_llaf341-B32","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"key":"2025112512425141000_llaf341-B33","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1684\/ejd.2018.3444","article-title":"Alemtuzumab is an effective third-line treatment versus single-agent gemcitabine or pralatrexate for refractory S\u00e9zary syndrome: a systematic review","volume":"28","author":"Stewart","year":"2018","journal-title":"Eur J Dermatol"},{"key":"2025112512425141000_llaf341-B34","author":"US Food and Drug Administration"},{"key":"2025112512425141000_llaf341-B35","author":"Misher"},{"key":"2025112512425141000_llaf341-B36","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1111\/jdv.15526","article-title":"Epidemiology and prognostic factors for mycosis fungoides and S\u00e9zary syndrome in a multi-ethnic Asian cohort: a 12-year review","volume":"33","author":"Lim","year":"2019","journal-title":"J Eur Acad Dermatol Venerol"},{"key":"2025112512425141000_llaf341-B37","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ad.2016.08.009","article-title":"Clinicopathologic variants of mycosis fungoides","volume":"108","author":"Mu\u00f1oz-Gonz\u00e1lez","year":"2017","journal-title":"Actas Dermosifiliogr"},{"key":"2025112512425141000_llaf341-B38","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1468-3083.2004.00937.x","article-title":"Clinicopathological spectrum of mycosis fungoides","volume":"18","author":"Kazakov","year":"2004","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025112512425141000_llaf341-B39","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.mpdhp.2024.11.003","article-title":"Rare variants of mycosis fungoides: a practical approach with emphasis on differential diagnosis","volume":"31","author":"Cazzato","year":"2025","journal-title":"Diagn Histopathol"},{"key":"2025112512425141000_llaf341-B40","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ijwd.2016.11.006","article-title":"Defining the mimics and clinico-histological diagnosis criteria for mycosis fungoides to minimize misdiagnosis","volume":"3","author":"Kelati","year":"2017","journal-title":"Int J Womens Dermatol"},{"key":"2025112512425141000_llaf341-B41","doi-asserted-by":"crossref","first-page":"169","DOI":"10.5826\/dpc.0903a01","article-title":"Dermoscopy of inflammatory dermatoses (inflammoscopy): an up-to-date overview","volume":"9","author":"Errichetti","year":"2019","journal-title":"Dermatol Pract Concept"},{"key":"2025112512425141000_llaf341-B42","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/bjd.12685","article-title":"Dermoscopy in general dermatology: practical tips for the clinician","volume":"170","author":"Lallas","year":"2014","journal-title":"Br J Dermatol"},{"key":"2025112512425141000_llaf341-B43","author":"Tucker"},{"key":"2025112512425141000_llaf341-B44","author":"Yee"},{"key":"2025112512425141000_llaf341-B45","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1053\/j.semdp.2017.11.003","article-title":"Drug induced pseudolymphoma","volume":"35","author":"Magro","year":"2018","journal-title":"Semin Diagn Pathol"},{"key":"2025112512425141000_llaf341-B46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2133.2006.07526.x","article-title":"Mycosis fungoides: a dermatological masquerader","volume":"156","author":"Nashan","year":"2007","journal-title":"Br J Dermatol"},{"key":"2025112512425141000_llaf341-B47","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s13555-020-00429-0","article-title":"Cicatricial alopecia related to folliculotropic mycosis fungoides","volume":"10","author":"Kreutzer","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2025112512425141000_llaf341-B48","author":"National Institute of Health and Care Excellence, Clinical Knowledge Summaries"},{"key":"2025112512425141000_llaf341-B49","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.3390\/diagnostics13111979","article-title":"Role of neutrophil-to-lymphocyte ratio (NLR) in patients with mycosis fungoides","volume":"13","author":"Di Raimondo","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"2025112512425141000_llaf341-B50","author":"Vaidya"},{"key":"2025112512425141000_llaf341-B51","author":"Ngan"},{"key":"2025112512425141000_llaf341-B52","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.critrevonc.2007.08.004","article-title":"Mycosis fungoides","volume":"65","author":"Zinzani","year":"2008","journal-title":"Crit Rev Oncol Hematol"},{"key":"2025112512425141000_llaf341-B53","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1001\/archderm.134.8.949","article-title":"Topical corticosteroids for mycosis fungoides. Experience in 79 patients","volume":"134","author":"Zackheim","year":"1998","journal-title":"Arch Dermatol"},{"key":"2025112512425141000_llaf341-B54","author":"Cutaneous Lymphoma Foundation"},{"key":"2025112512425141000_llaf341-B55"},{"key":"2025112512425141000_llaf341-B56","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1182\/blood-2008-10-184168","article-title":"Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases","volume":"113","author":"Bradford","year":"2009","journal-title":"Blood"},{"key":"2025112512425141000_llaf341-B57","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3389\/fonc.2019.00260","article-title":"Skin directed therapy in cutaneous T-cell lymphoma","volume":"9","author":"Tarabadkar","year":"2019","journal-title":"Front Oncol"},{"key":"2025112512425141000_llaf341-B58","first-page":"367","article-title":"The utility of bexarotene in mycosis fungoides and S\u00e9zary syndrome","volume":"8","author":"Panchal","year":"2015","journal-title":"Onco Targets Ther"},{"key":"2025112512425141000_llaf341-B59","author":"Macmillan Cancer Support"},{"key":"2025112512425141000_llaf341-B60","author":"Cutaneous Lymphoma Foundation"},{"key":"2025112512425141000_llaf341-B61","author":"US Food and Drug Administration"},{"key":"2025112512425141000_llaf341-B62","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3389\/fmed.2019.00116","article-title":"Novel and future therapeutic drugs for advanced mycosis fungoides and S\u00e9zary syndrome","volume":"6","author":"Oka","year":"2019","journal-title":"Front Med (Lausanne)"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llaf341\/63867538\/llaf341.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/12\/2365\/63867538\/llaf341.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/12\/2365\/63867538\/llaf341.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T17:43:04Z","timestamp":1764092584000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/50\/12\/2365\/8215592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":62,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,7,28]]},"published-print":{"date-parts":[[2025,11,25]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llaf341","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,7,28]]}}}